Given that ABCC1 is among the highest expressed ABC transporters in AML and its selective role in efflux of BH3 mimetics, our results highlight the importance of future studies in larger patient cohorts to further establish the role of ABCC1 as a biomarker that predicts the response to BCL-2 inhibition in AML. Here, BCL2 is linked to acute myeloid leukemia.